On November 28, 2018 Geron Corporation (Nasdaq: GERN) reported that the Company’s analyst and investor event will take place in New York, N.Y., on Monday, December 10, 2018 (Press release, Geron, NOV 28, 2018, View Source [SID1234531717]). Management will be joined by clinical investigators from both IMerge and IMbark who will reprise oral presentations from the 60th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting occurring in early December, as well as discuss the unmet medical need in hematologic myeloid malignancies. The event will begin at 8:00 a.m. ET.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Azra Raza, M.D., Chan Soon-Shiong Professor of Medicine and Director of the MDS Center in New York, will review data from Part 1 of the ongoing Phase 2/3 IMerge clinical trial of the telomerase inhibitor imetelstat in patients with lower risk myelodysplastic syndromes, including more mature efficacy and safety data from the combined initial and expansion cohorts presented at ASH (Free ASH Whitepaper).
John Mascarenhas, M.D., Associate Professor of Medicine in the Myeloproliferative Disorders Program of the Tisch Cancer Institute, Division of Hematology/Oncology at the Icahn School of Medicine at Mount Sinai, will review data from IMbark, the ongoing Phase 2 clinical trial of imetelstat in patients with Intermediate-2 or High-risk myelofibrosis, including more mature data from the extension phase of IMbark presented at ASH (Free ASH Whitepaper), including median overall survival.
Analysts and investors in attendance will be able to ask questions of the investigators during the question and answer session following the presentations. In addition, the Company will also discuss its development plans for imetelstat, including the start of the Phase 3 portion of IMerge by mid-year 2019.
A live audio webcast of the event will be available on Geron’s website, www.geron.com/investors/events. If you are unable to listen to the live event, an archived webcast of the event will be available on the Company’s website for 30 days